Press release – Medac Finland – 10-years anniversary symposium

Enhancing the potential of methotrexate.

Optimise  rheumatism  treatment  in  Finland  with  Metoject®   PEN   and ensure long-term success of therapy

Helsinki / Wedel (September 21, 2017). There is room for improvement in drug treatment of rheumatoid arthritis (RA) with the gold standard methotrexate (MTX). Current analyses of the FIN-ERA cohort suggest that Finnish rheumatology exploits the potential of methotrexate as initial treatment and follows the European treatment guidelines in a slightly adopted way focusing on combination therapy: “At baseline, 68 % used methotrexate-based combination therapy, and 31 % used triple therapy with methotrexate, hydroxychloroquine, and sulphasalazine (the Fin-RACo regimen)”.

Click here to view full Press release